Payment overview · 2025
General Payments
$455.70
23 reported records · 12 companies
Healthcare provider profile · identity verified
David Eugene Oakley, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TRAVERSE CITY, MI · NPI 1578523700
Verified facts
What the public records show
CMS Open Payments records show David Eugene Oakley, MD received $455.70 in general payments during 2025 across 23 reported records.
PFIZER INC. accounted for 17.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Shingrix, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Myrbetriq by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $80.29 | 17.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $65.52 | 14.4% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $54.38 | 11.9% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.59 | 10.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $48.41 | 10.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $40.11 | 8.8% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $29.83 | 6.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.14 | 4.6% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.26 | 4.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.23 | 4.2% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.04 | 3.1% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.90 | 3.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $455.70 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $80.29 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $47.76 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $43.69 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $40.11 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $38.71 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $29.83 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $29.14 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $25.11 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.48 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.27 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.23 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $17.76 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.04 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 153 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 56 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
153 | 35 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
29 | 29 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
56 | 49 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
153 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 651 | 181 |
| Lisinopril | Lisinopril | 415 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 380 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 380 | 100 |
| Losartan Potassium | Losartan Potassium | 287 | 78 |
| Omeprazole | Omeprazole | 260 | 82 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 59 |
| Alprazolam | Alprazolam | 208 | 51 |
| Simvastatin | Simvastatin | 190 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 164 | 50 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 49 |
| Gabapentin | Gabapentin | 157 | 42 |
| Eliquis | Apixaban | 153 | 35 |
| Trazodone Hcl | Trazodone Hcl | 151 | 44 |
| Meloxicam | Meloxicam | 135 | 38 |
| Metformin Hcl | Metformin Hcl | 131 | 40 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 123 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 109 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 105 | 29 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 103 | 31 |
| Atenolol | Atenolol | 102 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 96 | 29 |
| Allopurinol | Allopurinol | 93 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 24 |
| Tramadol Hcl | Tramadol Hcl | 84 | 25 |
| Potassium Chloride | Potassium Chloride | 81 | 21 |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 77 | 77 |
| Lorazepam | Lorazepam | 77 | 13 |
| Clonazepam | Clonazepam | 75 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 74 | 24 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 15 |
| Alendronate Sodium | Alendronate Sodium | 66 | 19 |
| Famotidine | Famotidine | 66 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 17 |
| Sertraline Hcl | Sertraline Hcl | 64 | 19 |
| Metformin Hcl Er | Metformin Hcl | 63 | 17 |
| Bupropion Hcl Sr | Bupropion Hcl | 62 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 60 | 14 |
| Celecoxib | Celecoxib | 57 | 15 |
| Finasteride | Finasteride | 57 | 11 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 56 | 49 |
| Carvedilol | Carvedilol | 55 | 16 |
| Furosemide | Furosemide | 53 | 21 |
| Mounjaro | Tirzepatide | 51 | suppressed |
| Prednisone | Prednisone | 49 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 28 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 14 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 41 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 11 |
| Estradiol | Estradiol | 39 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 37 | 14 |
| Azithromycin | Azithromycin | 35 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 35 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 16 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 18 |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 29 | 29 |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 29 | 24 |
| Sotalol | Sotalol Hcl | 28 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 28 | 22 |
| Dutasteride | Dutasteride | 27 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 17 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | 11 |
| Propranolol Hcl | Propranolol Hcl | 24 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Jardiance | Empagliflozin | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 21 | suppressed |
| Methylprednisolone | Methylprednisolone | 21 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Spironolactone | Spironolactone | 21 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 20 | 17 |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 14 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Ezetimibe | Ezetimibe | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 17 | suppressed |
| Eszopiclone | Eszopiclone | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | 12 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Baclofen | Baclofen | 14 | 11 |
| Nystatin | Nystatin | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Metronidazole | Metronidazole | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Torsemide | Torsemide | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Pregabalin | Pregabalin | 12 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $455.70 · 23 records | PFIZER INC. | AIRSUPRA, BREZTRI, ELIQUIS, GVOKE HYPOPEN, Kerendia, NURTEC ODT, OPSUMIT, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, Wegovy, ZORYVE | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error